Helius Medical Technologies (HSDT) shares were up more than 20% in recent trading Wednesday after the company said the newly published fee schedule payment rates for its portable neuromodulation stimulator are consistent with its preliminary reimbursement determination.
The Centers for Medicare and Medicaid Services on Monday posted final fee schedule payment rates for Medicare durable medical equipment, prosthetics, orthotics and supplies .
Price: 0.84, Change: +0.14, Percent Change: +20.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.